The combination of entinostat with selumetinib inhibited BRAFV600E HT-29 CRC xenograft growth, which was accompanied by increased H4 acetylation, reduced STAT3 activation, and apoptosis induction via caspase-3 activation [Table 2][97]. Here, STAT3 is linked to colorectal carcinoma.